[
  {
    "ts": null,
    "headline": "Inside the Trump Administration’s Vaccine Politics",
    "summary": "President Trump embraced antivaccine supporters. Now a crisis is unfolding at the Centers for Disease Control and Prevention under RFK Jr.",
    "url": "https://finnhub.io/api/news?id=2ae470d97051ba85386ee7c3866cbc534f20b7bebccf7cf3851a377e183f4837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756415220,
      "headline": "Inside the Trump Administration’s Vaccine Politics",
      "id": 136569358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump embraced antivaccine supporters. Now a crisis is unfolding at the Centers for Disease Control and Prevention under RFK Jr.",
      "url": "https://finnhub.io/api/news?id=2ae470d97051ba85386ee7c3866cbc534f20b7bebccf7cf3851a377e183f4837"
    }
  },
  {
    "ts": null,
    "headline": "Taking Profits For Yield And Growth With David Alton Clark",
    "summary": "David Alton Clark, The Winter Warrior Investor, thinks the market is a little bit toppy, feels good about shorter-term bonds, and is taking profits.",
    "url": "https://finnhub.io/api/news?id=90778682238704c1346b1a79dce13194dd8a184ccad6f2a83a56a2cfbe936527",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756400400,
      "headline": "Taking Profits For Yield And Growth With David Alton Clark",
      "id": 136564426,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1478156131/image_1478156131.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "David Alton Clark, The Winter Warrior Investor, thinks the market is a little bit toppy, feels good about shorter-term bonds, and is taking profits.",
      "url": "https://finnhub.io/api/news?id=90778682238704c1346b1a79dce13194dd8a184ccad6f2a83a56a2cfbe936527"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=58bf5e1402e569e017d66b464fcf962c0ba550542701536cb7790d74e69f2b73",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756399020,
      "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "id": 136572636,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=58bf5e1402e569e017d66b464fcf962c0ba550542701536cb7790d74e69f2b73"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Updated COVID-19 Vaccines but With Restrictions",
    "summary": "FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.",
    "url": "https://finnhub.io/api/news?id=441e5e43d762e4bac0a6a43beddabacad1db6db57e99b826e745b7f93e68c615",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756397040,
      "headline": "FDA Approves Updated COVID-19 Vaccines but With Restrictions",
      "id": 136563781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.",
      "url": "https://finnhub.io/api/news?id=441e5e43d762e4bac0a6a43beddabacad1db6db57e99b826e745b7f93e68c615"
    }
  },
  {
    "ts": null,
    "headline": "MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate",
    "summary": "Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.",
    "url": "https://finnhub.io/api/news?id=119d39afa8c3e6bfc439e7a1c59565c9920d3b3ea70ce6bcb3eca2b1e6df90da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756393980,
      "headline": "MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate",
      "id": 136563748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.",
      "url": "https://finnhub.io/api/news?id=119d39afa8c3e6bfc439e7a1c59565c9920d3b3ea70ce6bcb3eca2b1e6df90da"
    }
  },
  {
    "ts": null,
    "headline": "Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?",
    "summary": "ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.",
    "url": "https://finnhub.io/api/news?id=86cf60d6e6e33ce10c63e04c72fe20e9b4b243ffba53c2f6ee8489aa45b2e4d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756390200,
      "headline": "Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?",
      "id": 136560914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.",
      "url": "https://finnhub.io/api/news?id=86cf60d6e6e33ce10c63e04c72fe20e9b4b243ffba53c2f6ee8489aa45b2e4d5"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?",
    "summary": "Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.",
    "url": "https://finnhub.io/api/news?id=a72c3586afaa7ece6e70f2b2971d4a5c05086bda0c20505f68b074db1b0e3903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756387320,
      "headline": "Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?",
      "id": 136560799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.",
      "url": "https://finnhub.io/api/news?id=a72c3586afaa7ece6e70f2b2971d4a5c05086bda0c20505f68b074db1b0e3903"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves mRNA vaccines for new Covid-19 season amid political tension",
    "summary": "Moderna and Pfizer/BioNTech have secured formula updates to existing mRNA Covid-19 vaccines.",
    "url": "https://finnhub.io/api/news?id=52bb6444dd51a03066168011e4c4489567a1f5a98e41869e26a85f8637d7f372",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756382132,
      "headline": "FDA approves mRNA vaccines for new Covid-19 season amid political tension",
      "id": 136557968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna and Pfizer/BioNTech have secured formula updates to existing mRNA Covid-19 vaccines.",
      "url": "https://finnhub.io/api/news?id=52bb6444dd51a03066168011e4c4489567a1f5a98e41869e26a85f8637d7f372"
    }
  },
  {
    "ts": null,
    "headline": "Does Enanta’s EU Lawsuit Over Paxlovid Shift the Bull Case for Pfizer (PFE)?",
    "summary": "Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer and subsidiaries in the Unified Patent Court of the European Union, alleging that Pfizer’s COVID-19 antiviral Paxlovid infringes newly granted European Patent No. EP 4 051 265 across 18 EU countries. This legal challenge introduces significant uncertainty around a key revenue driver for Pfizer and comes as investor attention remains elevated due to both fundamental performance and shifting sentiment...",
    "url": "https://finnhub.io/api/news?id=71c4a70450405f59339de75a962f9c2b670e190fefe4a0451ffcdf6a2370236a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756375775,
      "headline": "Does Enanta’s EU Lawsuit Over Paxlovid Shift the Bull Case for Pfizer (PFE)?",
      "id": 136557969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer and subsidiaries in the Unified Patent Court of the European Union, alleging that Pfizer’s COVID-19 antiviral Paxlovid infringes newly granted European Patent No. EP 4 051 265 across 18 EU countries. This legal challenge introduces significant uncertainty around a key revenue driver for Pfizer and comes as investor attention remains elevated due to both fundamental performance and shifting sentiment...",
      "url": "https://finnhub.io/api/news?id=71c4a70450405f59339de75a962f9c2b670e190fefe4a0451ffcdf6a2370236a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A 6% Dividend Yield That Pays You To Stay Defensive",
    "summary": "Pfizer stock trades at a multi-year low with a 6.65% dividend yield. Click here for a full investment analysis of PFE stock.",
    "url": "https://finnhub.io/api/news?id=a1b1dc0d835dd47be4680be05e8d64b81b902e5874fbe03722a16b166c217847",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756372837,
      "headline": "Pfizer: A 6% Dividend Yield That Pays You To Stay Defensive",
      "id": 136557480,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer stock trades at a multi-year low with a 6.65% dividend yield. Click here for a full investment analysis of PFE stock.",
      "url": "https://finnhub.io/api/news?id=a1b1dc0d835dd47be4680be05e8d64b81b902e5874fbe03722a16b166c217847"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the 10 Best Affordable Stocks Under $50 to Buy. On August 5, Morgan Stanley increased its price target for Pfizer Inc. (NYSE:PFE) from $32 to $33 while keeping an Equalweight rating. This decision came after Pfizer Inc. (NYSE:PFE) released its Q2 2025 earnings report. The company continues to navigate […]",
    "url": "https://finnhub.io/api/news?id=8ca3056342f51caad5a170c82530b8551ae6923b3b2d4385d9fec05adb38c9f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756356475,
      "headline": "Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating",
      "id": 136557970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the 10 Best Affordable Stocks Under $50 to Buy. On August 5, Morgan Stanley increased its price target for Pfizer Inc. (NYSE:PFE) from $32 to $33 while keeping an Equalweight rating. This decision came after Pfizer Inc. (NYSE:PFE) released its Q2 2025 earnings report. The company continues to navigate […]",
      "url": "https://finnhub.io/api/news?id=8ca3056342f51caad5a170c82530b8551ae6923b3b2d4385d9fec05adb38c9f0"
    }
  },
  {
    "ts": null,
    "headline": "8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars",
    "summary": "8 of 14 'safer' lowest-priced GASV stocks are currently fair-priced and buyable. See here for top large-cap value stocks with strong dividends and intrinsic value.",
    "url": "https://finnhub.io/api/news?id=e94a5991d8b2690f00b92f09404f407f0a5b65e3dffb42e56aa53fdbf75214e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756353065,
      "headline": "8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars",
      "id": 136556312,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "8 of 14 'safer' lowest-priced GASV stocks are currently fair-priced and buyable. See here for top large-cap value stocks with strong dividends and intrinsic value.",
      "url": "https://finnhub.io/api/news?id=e94a5991d8b2690f00b92f09404f407f0a5b65e3dffb42e56aa53fdbf75214e5"
    }
  },
  {
    "ts": null,
    "headline": "Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting with Pfizer (NYSE:PFE).",
    "url": "https://finnhub.io/api/news?id=4c31394a84f16b0ef95881bb123ec46441f63a90a01cdb13d258c3a0c8ff6e1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756352130,
      "headline": "Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2",
      "id": 136560916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting with Pfizer (NYSE:PFE).",
      "url": "https://finnhub.io/api/news?id=4c31394a84f16b0ef95881bb123ec46441f63a90a01cdb13d258c3a0c8ff6e1d"
    }
  }
]